Brust Douglas, Polis Michael, Davey Richard, Hahn Barbara, Bacharach Stephen, Whatley Millie, Fauci Anthony S, Carrasquillo Jorge A
National Institute of Allergy and Infectious Disease, and the Nuclear Medicine Department, Warren G. Magnuson Clinical Center of the National Institutes of Health, 10 Center Drive, MSC 1180, Bethesda, MD 20892, USA.
AIDS. 2006 Apr 24;20(7):985-93. doi: 10.1097/01.aids.0000222070.52996.76.
Nodal uptake in areas of lymphocyte activation can be visualized using fluorodeoxyglucose. Various patterns of fluorodeoxyglucose accumulation in HIV-positive patients have been described previously and hypothesized potentially to represent regions of active HIV replication or nodal activation. We evaluated the utility of fluorodeoxyglucose scanning as a tool to study HIV pathogenesis.
We evaluated fluorodeoxyglucose biodistribution visually and quantitatively in HIV-negative individuals and various groups of HIV-infected patients to determine the impact on the pattern of nodal activation of HIV infection, the stage of HIV infection and degree of viremia, and HAART. In addition, we attempted to image anatomical site(s) of ongoing HIV replication in patients with suppressed HIV viremia on HAART, but subsequently discontinued HAART.
We performed fluorodeoxyglucose imaging on five groups: HIV-negative, HIV-positive individuals with early infection, HIV-positive patients with advanced disease, HIV-positive patients with suppressed viral loads, and HIV-positive patients who stopped HAART.
Healthy HIV patients with suppressed viral loads and HIV-negative individuals had no or little fluorodeoxyglucose nodal accumulation or any other hypermetabolic areas, whereas viremic individuals with early and advanced HIV had increased fluorodeoxyglucose in the peripheral nodes, indicating that fluorodeoxyglucose potentially identifies areas of HIV replication. Fluorodeoxyglucose biodistribution was similar between early and advanced-stage disease. Four of five patients taken off HAART had negative baseline scans but developed nodal uptake and increases in viral loads.
Abnormal fluorodeoxyglucose accumulation occurs in the nodes of individuals with detectable viral loads. Interruption of effective HAART results in the activation of previously quiescent nodal areas.
利用氟脱氧葡萄糖可使淋巴细胞活化区域的淋巴结摄取情况可视化。先前已描述了HIV阳性患者中氟脱氧葡萄糖的各种积聚模式,并推测其可能代表活跃的HIV复制区域或淋巴结活化区域。我们评估了氟脱氧葡萄糖扫描作为研究HIV发病机制工具的效用。
我们对HIV阴性个体以及不同组别的HIV感染患者进行了氟脱氧葡萄糖生物分布的视觉和定量评估,以确定HIV感染、HIV感染阶段、病毒血症程度和高效抗逆转录病毒治疗(HAART)对淋巴结活化模式的影响。此外,我们试图对接受HAART但病毒血症得到抑制、随后停用HAART的患者正在进行HIV复制的解剖部位进行成像。
我们对五组人群进行了氟脱氧葡萄糖成像:HIV阴性者、早期感染的HIV阳性个体、晚期疾病的HIV阳性患者、病毒载量得到抑制的HIV阳性患者以及停止HAART的HIV阳性患者。
病毒载量得到抑制的HIV阳性患者和HIV阴性个体没有或仅有很少的氟脱氧葡萄糖淋巴结积聚或任何其他高代谢区域,而处于HIV早期和晚期且有病毒血症的个体外周淋巴结中的氟脱氧葡萄糖增加,这表明氟脱氧葡萄糖可能识别出HIV复制区域。早期和晚期疾病患者的氟脱氧葡萄糖生物分布相似。五名停止HAART的患者中有四名基线扫描结果为阴性,但出现了淋巴结摄取且病毒载量增加。
在可检测到病毒载量的个体的淋巴结中会出现异常的氟脱氧葡萄糖积聚。有效的HAART中断会导致先前静止的淋巴结区域活化。